Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients

Ryuji Takahashi,1,6 Yukinao Ishibashi,2 Koji Hiraoka,2 Satoko Matsueda,3 Kouichirou Kawano,4 Akihiko Kawahara,5 Masayoshi Kage,6 Koichi Ohshima,5 Ryuya Yamanaka,3 Shigeki Shichijo,7 Kazuo Shirouzu,1 Kyogo Itoh3 and Tetsuro Sasada3

Departments of 1Surgery, 2Orthopedics, 3Immunology and Immunotherapy, 4Gynecology, 5Pathology, Kurume University School of Medicine, Kurume, Japan

(Received March 7, 2013 / Revised June 28, 2013 / Accepted June 30, 2013 / Accepted manuscript online July 6, 2013 / Article first published online August 6, 2013)

Refractory bone and soft tissue sarcomas are challenging diseases to treat because of their robustness to chemotherapy. Although cancer vaccines have the potential to become an attractive treatment modality, their progress has been hampered by the presence of many subtypes of sarcomas and different human leukocyte antigen (HLA)-types. We investigated whether personalized peptide vaccination (PPV) would be feasible for the vast majority of sarcoma patients. Twenty refractory bone and soft tissue sarcoma patients with nine different subtypes and 11 different HLA-class IA phenotypes were enrolled in this study. A maximum of four HLA-matched peptides showing higher peptide-specific IgG responses in pre-vaccination plasma were selected from 31 pooled peptide candidates applicable for the HLA-A2, -A3, -A11, -A24, -A26, -A31, and -A33 types, and were subcutaneously administered weekly for 6 weeks and bi-weekly thereafter. Measurement of peptide-specific CTL and IgG responses along with other laboratory analyses were conducted before and after vaccination. No patients were excluded by either sarcoma subtypes or different HLA-types. No severe adverse events associated with PPV were observed in any patients. Peptide-specific immunological boosting was observed in the post-vaccination samples from the majority of patients. Tumor reduction of the lung metastasis and a long stable disease was observed in each case, and the median overall survival time of the 20 cases was 9.6 months. Taken together, PPV could be feasible for the vast majority of refractory sarcoma patients because of the safety and higher rates of immunological responses regardless of the presence of different sarcoma subtypes and various HLA-types. (Cancer Sci 2013; 104: 1285–1294)

R
efractory bone and soft tissue sarcomas are challenging diseases to treat with an unmet need for effective systemic therapy.1,2 Several molecularly targeted agents, such as mammalian target of rapamycin (mTOR) inhibitor3 and antibody to the insulin-like growth factor 1 receptor (IGF-1R),4 have shown clinical benefits in a subgroup of sarcoma patients with refractory sarcomas, achieving a median survival time (MST) of 7.6–9.2 months. However, new treatment modalities still remain to be developed to improve overall survival (OS) of these patients, and cancer vaccines have been discussed as a promising approach against refractory sarcomas because of the expressions of tumor-associated antigens (TAA) on sarcoma tissues.1,2,5–9 Nevertheless, there have been few clinical trials of cancer vaccination for refractory sarcoma patients. One of the hurdles could be the fact that there are many sarcoma subtypes along with different human leukocyte antigen (HLA)-types.

We have developed a novel regime of personalized peptide vaccination (PPV), in which vaccine antigens are selected and administered from a pool of 31 different peptide candidates based on the pre-existing IgG responses specific to peptides before vaccination.10–13 In previous studies, the PPV was feasible for the vast majority of cancer patients with different HLA-types.10–13 A recently conducted randomized clinical trial of PPV in advanced prostate cancer patients showed a favorable clinical outcome in the vaccinated group.14 In the present study, we addressed whether PPV treatment would be feasible for refractory bone and soft tissue sarcoma patients with various HLA-types by conducting a small-scale phase II study.

Materials and Methods

TAA and HLA-class I expressions in sarcoma tissues. The expressions of 15 different TAA, from which the vaccine peptides used for PPV were derived, were examined by immunohistochemistry (IHC) in 26 sarcoma tissues (11 leiomyosarcoma, five synovial sarcoma, five malignant fibrous histiocytoma, and five liposarcoma) as previously reported.15 The expression of HLA-class I was also examined by IHC in the 26 sarcoma tissues by using an anti-HLA-class I antibody (murine monoclonal, clone EMR8-5; Abcam, Cambridge, UK).

Patients. Patients with histological diagnosis of bone and soft tissue sarcoma were eligible for inclusion in the present study. All patients were required to have evaluable recurrent and/or metastatic tumors at the time of entry. Patients whose general condition was tolerable for chemotherapy or radiotherapy were eligible only after the failure of these therapies. Patients, who had poor general conditions intolerable for chemotherapy or radiotherapy, or refused them, were also eligible. All patients were required to show positive IgG responses to at least two of the 31 different vaccine candidate peptides, as reported previously.10–12 Other inclusion criteria were as follows: age between 20 and 80 years; an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; positive status for the HLA-A2, -A24, -A3 supertypes (A3, A11, A31, or A33), or -A26 types; life expectancy of at least 12 weeks; and adequate hematologic, hepatic, and renal function. Exclusion criteria included pulmonary, cardiac, or other systemic diseases; an acute infection; a history of severe allergic reactions; pregnancy or nursing; and other inappropriate conditions for enrollment as judged by clinicians. Patients with a lymphocyte count of <1000/μL were excluded from the study, since we previously reported that pre-vaccination lymphocytopenia (<1000 cells/μL) is an unfavorable factor for OS in cancer patients receiving PPV.16,17 The protocol was approved by the Kurume University Ethical Committee and registered in the UMIN Clinical Trials Registry
All patients were given a full explanation of the protocol and provided their informed consent before enrollment.

**Clinical protocol.** This was a phase II study to evaluate the safety and immunological responses in refractory bone and soft tissue sarcoma patients under PPV. Thirty-one peptides, whose safety and immunological effects for other types of cancer were confirmed in previously conducted clinical studies, were used for vaccination (12 peptides for HLA-A2, 16 peptides for HLA-A24, nine peptides for HLA-A3 supertypes [-A3, -A11, -A31, and -A33], and four peptides for HLA-A26) (Table S1). These peptides were prepared under the condition of Good Manufacturing Practice (GMP) by the PolyPeptide Laboratories (San Diego, CA, USA) and American Peptide Company (Vista, CA, USA). Peptides for vaccination to individual patients were selected in consideration of the pre-existing host immunity before vaccination, as assessed by the titers of IgG specific to each of the 31 different vaccine candidates.

A maximum of four peptides (3 mg/each peptide), which were selected based on the results of HLA typing and peptide-specific IgG titers, were subcutaneously administrated with incomplete Freund’s adjuvant (Montanide ISA51; Seppic, Paris, France) once a week for six consecutive weeks. After the first cycle of six vaccinations, up to four antigen peptides, which were re-selected according to the titers of peptide-specific IgG at the 6th vaccination, were administered every 2 weeks. During the PPV, patients were allowed to receive combination therapies, such as chemotherapies or radiotherapies. Since the frequency of bone and soft tissue sarcomas had been low, we enrolled the patients treated both with and without combination therapies to facilitate the enrolment. Adverse events were monitored according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTC Ver.-3.0). Complete blood counts and serum biochemistry tests were performed every six vaccinations. The clinical responses were determined by the Response Evaluation Criteria in Solid Tumors (RECIST) in the vaccinated patients. The RECIST-based clinical responses were evaluated every six vaccinations by radiological findings of computed tomography (CT) scan and/or magnetic resonance imaging (MRI), and the

---

**Fig. 1.** Expressions of tumor-associated antigens (TAA) in soft tissue sarcoma tissues. Expressions of TAA were examined by immunohistochemistry in soft tissue sarcoma tissues. Thirteen out of the 15 TAA were expressed at different frequencies in soft tissue sarcoma tissues. Representative results are shown (a–m: ×400). The remaining two prostate-related antigens, PSA and PSMA, were not detectable by immunohistochemistry in sarcoma tissues tested (not shown).
best overall responses during PPV treatment were shown. For the patients who did not complete the first cycle of six vaccinations, the newest radiological findings were evaluated.

**Measurement of humoral and cellular immune responses and inflammatory cytokine and markers.** Humoral immune responses specific to each of the 31 peptide candidates were determined by peptide-specific IgG levels using the Luminex system (Luminex, Austin, TX, USA), as previously reported. If the titers of peptide-specific IgG to at least one of the vaccinated peptides in the post-vaccination plasma were more than two-fold higher than those in the pre-vaccination plasma, the changes were considered to be significant as reported previously. Cellular immune responses specific to the vaccinated peptides were evaluated by interferon (INF)-γ ELISPOT using PBMCs as reported previously. As a control, cellular immune responses specific to CEF peptides (MABTECH, Cincinnati, OH, USA), a mixture of virus-derived CTL epitopes, were also examined. Inflammatory cytokine and markers, including interleukin-6 (IL-6), C-reactive protein (CRP), and serum amyloid A (SAA), in plasma samples were also examined by ELISA as reported previously.

**Statistical analysis.** The two-sided Wilcoxon test was used to examine differences between pre- and post-vaccination measurements. *P*-values <0.05 were considered to be statistically significant. Progression-free survival (PFS) or OS were calculated from the date of the first vaccination until the date of disease progression or death, respectively, or the last date when the patient was known to be alive. Predictive factors for OS

![Fig. 2. Expressions of HLA-class I in soft tissue sarcoma tissues.](image-url)

Expressions of HLA-class I were examined by immunohistochemistry in different subtypes of soft tissue sarcoma tissues. (a,b) leiomyosarcoma (a, ×200; b, ×400). (c,d) synovial sarcoma (c, ×200; d, ×400). (e,f) liposarcoma (e, ×200; f, ×400). (g,h) malignant fibrous histiocytoma (g, ×200; h, ×400).
Table 1. Characteristics of the enrolled patients with refractory sarcoma

| No. | HLA type  | Sex  | Age | Pathology          | Stage | PS Previous radiotherapy | No. of previous chemotherapy | Periods of chemotherapy | Disease location         | No. of vaccination | Combined therapy | Treatment response | PFS | Survival times |
|-----|-----------|------|-----|--------------------|-------|--------------------------|-----------------------------|--------------------------|------------------------|---------------------|------------------|-------------------|------|-----------------|
| 1   | A2/A24    | M    | 64  | Osteosarcoma       | rec. 0| +                        | 2                           | 23.0                     | Lung                   | 12                 | –                | PD                | 4.8 | 9.7            |
| 2   | A2/A11    | M    | 31  | Malignant neurinoma| rec. 0| +                        | 1                           | 6.8                      | Lung, Mediastinal LN    | 17                 | –                | SD                | 6.8 | 7.6            |
| 3   | A2/A24    | M    | 60  | MFH                | rec. 0| –                        | –                           | 32.0                     | Lung, Inguinal LN       | 6                  | –                | PD                | 2.0 | 2.3†           |
| 4   | A2/A24    | F    | 30  | Synovial sarcoma   | rec. 0| +                        | 2                           | 8.9                      | Lung                   | 6                  | Radiotherapy      | PD                | 1.8 | 4.6            |
| 5   | A2/A26    | M    | 54  | Synovial sarcoma   | IV    | 0                        | 1                           | 10.0                     | Mediastinal LN          | 6                  | –                | SD                | 33.0 | 35.0†          |
| 6   | A24/A33   | F    | 74  | Liposarcoma        | rec. 1| +                        | –                           | –                        | Humerus, Thoracic vertebra| 14                 | –                | SD                | 7.4 | 9.2†           |
| 7   | A11/A33   | F    | 49  | Leiomyosarcoma     | IV    | 0                        | 2                           | 3.8                      | Lung, Liver, Sacrum     | 15                 | –                | PD                | 4.5 | 10.0          |
| 8   | A33       | F    | 23  | Osteosarcoma       | rec. 0| –                        | 4                           | 6.9                      | Lung, Hilar LN          | 4                  | –                | PD                | 1.6 | 2.2            |
| 9   | A24/A33   | M    | 43  | Epithelioid sarcoma| rec. 1| +                        | –                           | –                        | Parasternal LN, Pleura  | 12                 | –                | SD                | 7.0 | 25.0†          |
| 10  | A24       | F    | 33  | Leiomyosarcoma     | rec. 0| –                        | 3                           | 17.0                     | Lung, Liver, Peritoneum | 12                 | GEM + DTX        | PD                | 4.4 | 9.6            |
| 11  | A24/A26   | F    | 62  | Liposarcoma        | rec. 0| –                        | 2                           | 2.7                      | Liver, Retroperitoneum  | 4                  | –                | PD                | 1.5 | 7.2            |
| 12  | A24/A26   | F    | 55  | Clear cell sarcoma| rec. 1| –                        | 3                           | 4.6                      | Intraabdominal LN       | 6                  | –                | PD                | 3.5 | 21.0†          |
| 13  | A24       | M    | 73  | MFH                | rec. 0| –                        | –                           | –                        | Lung, Liver             | 11                 | –                | SD                | 11.0 | 11.0          |
| 14  | A26/A30   | F    | 38  | MFH                | rec. 1| –                        | 2                           | 2.3                      | Liver, Retroperitoneum  | –                  | –                | PD                | 1.4 | 2.5            |
| 15  | A24       | F    | 75  | Leiomyosarcoma     | rec. 0| –                        | –                           | –                        | Liver, Lumbar vertebra, Sacrum, Femur| 12                 | –                | PD                | 4.4 | 6.2            |
| 16  | A2/A24    | M    | 64  | Chondrosarcoma     | rec. 0| –                        | –                           | –                        | Lung, Pleura            | 14                 | –                | SD                | 5.7 | 5.7†           |
| 17  | A2        | F    | 63  | Leiomyosarcoma     | rec. 0| +                        | 3                           | 24.0                     | Lung, Subcutaneous tissue| 6                  | GEM              | PD                | 1.8 | 4.7            |
| 18  | A2/A11    | M    | 71  | Osteosarcoma       | rec. 0| –                        | –                           | –                        | Local recurrence, Lung  | 11                 | –                | PD                | 3.5 | 4.1†           |
| 19  | A2/A26    | M    | 45  | Alveolar soft part sarcoma | rec. 0| +                        | 3                           | 65.0                     | Lung, Brain             | 10                 | Radiotherapy CPA| PD                | 3.5 | 3.6†           |
| 20  | A11/A31   | M    | 27  | Synovial sarcoma   | rec. 0| –                        | 2                           | 8.9                      | Lung, Liver, Retroperitoneum| 6                  | Sorafenib        | PD                | 1.6 | 3.2            |

†Survivor. CPA, cyclophosphamide; DTX, docetaxel; F, female; GEM, gemcitabine; LN, lymph nodes; M, male; MFH, malignant fibrous histiocytoma; PS, performance status; PD, progressive disease; PFS, progression-free survival; rec., recurrent status; SD, stable disease.
were evaluated by univariate analysis with the Cox proportional hazards regression model.

Results

TAA and HLA-class I expressions in sarcoma tissues. Figures 1 and 2 show the representative data of TAA and HLA-class I expressions in soft tissue sarcoma tissues determined by IHC. Thirteen out of 15 TAA were expressed at different frequencies in soft tissue sarcoma tissues, as follows: Cyclophilin B, 20/26 (77%); ppMAPkkk, 15/26 (58%); WHSC2, 23/26 (88%); HRNPL, 25/26 (96%); UBE2V, 17/26 (65%); SART3, 26/26 (100%); SART2, 26/26 (100%); EGF-R, 17/26 (65%); EZH2, 13/26 (50%); PTHrP, 9/26 (35%); PAP, 13/26 (50%); p56lk, 7/26 (27%); MRP3, 3/26 (12%). However, the remaining two prostate-related antigens (PSA and PSMA) were not detectable by IHC (data not shown). HLA-class I was expressed in 25 of 26 various subtypes of sarcoma tissues examined, except for one synovial sarcoma tissue.

Patients’ characteristics. Between August 2009 and May 2012, 20 patients with refractory bone and soft tissue sarcoma (leiomyosarcoma, n = 4; osteosarcoma, n = 3; synovial sarcoma, n = 3; malignant fibrous histiocytoma, n = 3; liposarcoma, n = 2; chondrosarcoma, n = 1; malignant neurinoma, n = 1; epithelioid sarcoma, n = 1; clear cell sarcoma, n = 1; alveolar soft part sarcoma, n = 1), were enrolled in this study. Table 1 shows the clinicopathological characteristics of the 20 patients (10 male and 10 female). Performance status at the time of enrollment was grade 0 (n = 16) or grade 1 (n = 4). Five patients (#6, #15, #18, #20, and #22; all >60-year-old) had received neither chemotherapy nor radiotherapy because they refused these treatments or their general condition was not tolerable for them. The median age was 55 years, ranging from 23 to 75 years. Thirteen patients had received unsuccessful chemotherapy. The median duration of previous chemotherapy was 8.9 months, ranging from 2.3 to 65 months. Patients received one (n = 2), two (n = 5), three (n = 4), or four (n = 2) chemotherapy regimens, and the median number of chemotherapy regimens was two. The median duration from the first recurrence to the PPV was 13 months, ranging from 1 to 76 months. Seven patients had received unsuccessful radiotherapy. Of the total 20 patients, 17 completed the first cycle of vaccinations, whereas the remaining three patients failed
due to rapid disease progression. The median number of vaccinations was 10, ranging from 3 to 17. During the PPV, three patients were treated in combination with chemotherapies, and two patients were treated with radiotherapies, while the remaining 15 patients had no combination therapies.

**Toxicities.** Grade 1 or 2 dermatological reaction at the injection sites was observed in all cases (Table 2). Anemia (n = 14), lymphocytopenia (n = 14), and hypoalbuminemia (n = 10) were observed frequently. Grade 3 adverse events included anemia (n = 2), lymphocytopenia (n = 1), thrombocytopenia (n = 1), and hypoalbuminemia (n = 1). According to evaluation by the independent safety evaluation committee in this trial, all of these Grade 3 adverse events were concluded to be not directly associated with the PPV, but with the disease progression.

**Immune responses to the vaccinated peptides.** Both humoral and cellular immune responses specific to the vaccinated peptides were analyzed in blood samples before and after vaccination (Table 3). Plasma samples were collected from 20 and 17 patients before and at the 6th vaccinations, respectively.

| Patient No. | Peptide       | IgG response† | CTL response‡ |
|-------------|---------------|---------------|---------------|
|             | Before | 1st   | Before | 1st   |
| 14          | SART3-109 | 20    | NA     | 0     | NA    |
|             | WHSC2-103  | 15    | NA     | 0     | NA    |
|             | CEF      | NA    | NA     | 0     |         |
| 15          | SART2-93  | 3348  | 2612   | 0     | 0     |
|             | PSA-248   | 189   | 12,486 | 0     | 0     |
|             | Lck-488   | 94    | 3314   | 0     | 103   |
|             | PTHPr-102 | 47    | 69     | 0     | 0     |
|             | CEF      | NA    | NA     | 0     |         |
| 16          | WHSC2-103 | 1000  | 1115   | 409   | 2773  |
|             | SART3-109 | 1665  | 1774   | 0     | 0     |
|             | MRP3-1293 | 298   | 265    | 0     | 0     |
|             | Lck-488   | 225   | 226    | 0     | 2084  |
|             | CEF      | NA    | 4558   | 3699  |       |
| 17          | GypB-129  | 93    | 55     | 0     | 0     |
|             | WHSC2-103 | 110   | 52     | 0     | 0     |
|             | HNRPL-501 | 158   | 5472   | 0     | 0     |
|             | WHSC2-141 | 116   | 78     | 0     | 0     |
|             | CEF      | NA    | 5256   | 8402  |       |
| 18          | Lck-422   | 11    | 0      | 0     | 713   |
|             | SART3-309 | 13    | 16     | 0     | 0     |
|             | SART3-734 | 783   | 6089   | 0     | 1418  |
|             | Lck-90    | 21    | 25     | 0     | 0     |
|             | CEF      | NA    | 1631   | 2640  |       |
| 19          | ppMAPkkk-432 | 132   | 148    | 0     | 0     |
|             | HNRPL-140 | 60    | 0      | 0     | 417   |
|             | SART3-302 | 68    | 400    | 0     | 347   |
|             | SART3-109 | 259   | 364    | 0     | 0     |
|             | CEF      | NA    | 3459   | 2439  |       |
| 20          | SART3-734 | 369   | 328    | 0     | 0     |
|             | Lck-90    | 64    | 53     | 0     | 0     |
|             | GypB-129  | 48    | 40     | 0     | 0     |
|             | WHSC2-103 | 43    | 75     | 0     | 0     |
|             | CEF      | NA    | 1486   | 2483  |       |

†Values indicate the fluorescence intensity unit (FIU) of plasma IgG reactive with the corresponding peptides before and after the 1st cycle of vaccination. The augmented IgG responses are underlined. ‡Values indicate the number of spots per 10⁵ peripheral blood mono-nuclear cells (PBMCs) reactive with the corresponding peptides in IFN-γ ELISPOT assay before and after the 1st cycle of vaccinations. When the number of spots was <30 per 10⁵ PBMCs, the data are shown as “0”. The augmented T cell responses are underlined. CEF, a mixture of virus-derived CTL epitopes; NA, not assessed.

Plasma samples from three patients, who failed to complete the first cycle of six vaccinations due to disease progression, were unavailable. For the monitoring of humoral immune responses, peptide-specific IgG reactive to each of the 31 different peptides, including both vaccinated and non-vaccinated peptides, were measured by bead-based multiplex assay. The numbers of peptides used for the first cycle of vaccinations were 2, 3, or 4 in 3, 1 or 16 patients, respectively (Table 3). Augmentation of the IgG responses specific to at least one of the vaccinated peptides after vaccination was observed in 11 of 17 patients (64.7%). We also evaluated epitope spreading by comparing the peptide-specific IgGs to non-vaccinated peptides in plasma before and after vaccination. As a result, 12 of 17 patients (70.6%) showed epitope spreading to at least one of the non-vaccinated peptides (Table S2).

**Cellular immune responses to the vaccinated peptides were assessed by INF-γ ELISPOT assay (Table 3).** Antigen-specific CTL responses were detectable in only three of 20 patients before vaccination. In contrast, augmentation of the CTL responses specific to at least one of the vaccinated peptides after vaccination was observed in 12 of 17 patients (70.6%). We also tested CTL responses to CEF peptides, a mixture of virus-derived CTL epitopes, as a control. Cytotoxic T-lymphocyte responses to CEF peptides were observed in 9 of 20 (45%) patients before vaccination and 8 of 17 (47%) patients after vaccination, respectively.

Collectively, eight patients showed both increased CTL and IgG responses to the vaccinated peptides. 16 of 17 patients showed either increased CTL or IgG responses, and the remaining one patient showed neither CTL nor IgG boosting. There were no significant differences in increase in CTL or IgG responses between the patients treated with PPV alone (n = 12) and those treated with combination therapies (n = 5) (P = 0.794 and P = 0.543, respectively; $\chi^2$ test).

**Inflammatory cytokine and markers.** We measured inflammation cytokine and markers, including IL-6, CRP and SAA, in the plasma before and at the 6th vaccination. IL-6 was detectable in 12 patients before vaccination with a median of 2.5 pg/mL, ranging from 0 to 60 pg/mL. IL-6 levels were increased.
decreased, or unchanged in nine, five, or three patients tested, respectively (Table 4). A significant increase was observed in IL-6 levels after vaccination ($P = 0.034$, Wilcoxon test).

An inflammation marker, CRP, was detectable in the pre-vaccination plasma of 19 patients with a median value of 5.3 mg/dL (ranging from 0 to 16 mg/dL). Plasma CRP levels were increased, decreased, or unchanged in 11, 5, or 1 patients, respectively (Table 4). Another inflammation marker, SAA, was also detected in the pre-vaccination plasma of 18 patients with a median value of 73.5 mg/dL (ranging from 0 to 180 mg/dL). Plasma SAA levels were increased or decreased in 10 or 7 patients, respectively (Table 4). There was a significant increase in the levels of CRP after vaccination ($P = 0.027$, Wilcoxon test), while there was no significant difference in the levels of SAA between before and after vaccination ($P = 0.178$, Wilcoxon test).

**Clinical responses and biomarker analysis.** Best clinical responses were evaluated by radiological findings. There were no complete response (CR), no partial response (PR), six stable disease (SD), and 14 progressive disease (PD; Table 1). Computed tomography findings of two SD cases before and after the 6th vaccination are shown in Figure 3. One of the SD cases (case #13 in Table 1) was a 72-year-old man with recurrent malignant fibrous histiocytoma treated with PPV alone. At 4 months after the first vaccination, the lung metastasis was remarkably reduced in size (Fig. 3a,b), but the liver metastasis showed no changes in size. Another SD case (case #5 in Table 1) was a 54-year-old man with advanced synovial sarcoma, who was also treated with PPV alone. He had a huge mediastinal tumor, which showed no increase in size for a period of 34 months after the first vaccination (Fig. 3c,d). The cellular immune responses to vaccinated peptides were well boosted in both cases, while IgG responses to vaccine peptides were not boosted in one of them (case #13 in Table 3).

The median survival time (MST) and median progression-free survival time (MPFST) of the 20 patients was 9.6 months (95% confidence interval [CI], 4.7–11.0 months) and 4 months (95% CI, 1.8–6.8 months; Fig. 4). The MST and MPFST of the five patients treated with PPV plus combination therapies were significantly worse than those of the 15 patients treated with PPV alone (MST, 4.7 vs 10 months, $P = 0.037$; MPFS, 1.8 vs 4.5 months, $P = 0.045$; Fig. S1a,b). Under these circumstances, the Cox proportional hazards model was used to identify prognostic factors for OS. In the univariate analysis with pre-vaccination data, lymphocytopenia and higher levels of IL-6 were unfavorable factors for OS ($P = 0.020$ and $P = 0.014$, respectively). To better understand their involvement, a log-rank test was used for the statistical analysis. The
patients with lymphocytopenia (<1500/µL; \( P = 0.071 \)) or higher levels of IL-6 (≥4 pg/mL; \( P = 0.035 \)) in the pre-vaccination samples showed shorter OS (Fig. 5). The univariate analysis with post-vaccination data at the time of the 6th vaccination showed that the epitope spreading to at least three of the non-vaccinated peptides was the favorable factor for OS (\( P = 0.020 \)). A log-rank test also showed that the presence of epitope spreading to at least three of the non-vaccinated peptides in the post-vaccination samples showed longer OS (\( P = 0.020 \); Fig. 6).

Discussion

By IHC analysis, 13 out of 15 TAA, from which the vaccine peptides used for PPV were derived, were expressed in all subtypes of sarcoma tissues examined (leiomyosarcoma, synovial sarcoma, malignant fibrous histiocytoma, and liposarcoma). In addition, HLA-class I was expressed in almost all of the sarcoma tissues examined, except for one synovial sarcoma tissue. These results suggest that these TAA could be used as a target of immunotherapy for refractory sarcoma patients. In contrast, two prostate-related antigens, PSA and PSMA, whose expressions were primarily restricted to prostate cancers, were not detectable by IHC analysis in sarcoma tissues. Nevertheless, only five among 74 peptides that were vaccinated to 20 patients at the first cycle were derived from either PSA (four cases) or PSMA (one case; Table 3). Considering there was no expression of prostate-related antigens in sarcoma tissues examined, PSA- and PSMA-derived peptides should be selected only for patients who have no IgG responses to the other peptides in the next PPV trial for sarcoma patients, as reported previously.\(^{(11)}\)

The phenotypes of HLA-class IA antigens of the 20 patients were very diverse, with the HLA-A24, -A2, -A26, -A11, -A33, -A30, and -A31 types occurring in 11, 9, 5, 4, 3, 1, and 1 case, respectively. These frequencies are expected based on previous reports in the Japanese population.\(^{(15)}\) Importantly, peptide-specific CTL or IgG boosting after vaccination was observed in the majority of patients tested, regardless of the different histological types of sarcoma cells and different HLA-types. It is also of note that only 3 of 20 patients showed peptide-specific CTL responses in pre-vaccination PBMCs, but CTL responses became detectable in 12 of 17 patients after vaccination. On the contrary, the frequencies of CTL responses to virus-related peptides were not different between the pre- (9 of 20 cases) and post-vaccination (8 of 17 cases) samples. These results suggest that immune boosting was really restricted to the vaccinated peptides, and did not inhibit cellular immunity to infectious viruses.
In addition, no severe adverse events related to PPV were observed. These findings suggest that PPV using 31 vaccine peptide candidates could be feasible for the vast majority of sarcoma patients at least in Japan, and probably also worldwide, since the seven different HLA-types mentioned above along with the HLA-A3 type would be expected to cover the vast majority of sarcoma patients.

In the pre-vaccination samples, the lymphocytopenia and higher levels of IL-6 were inversely correlated with OS. IL-6 is a multifunctional cytokine that regulates various aspects of immune responses, acute phase reactions, and hematopoiesis.\(^{(19,20)}\) In addition, IL-6 has recently been reported to be one of the critical cytokines for inducing suppressive immune cell subsets, such as myeloid-derived suppressor cells and Th17, which are known to negatively affect anti-tumor immunity.\(^{(21)}\) It thus might be possible that high levels of IL-6 inhibit immune responses to cancer vaccines. In the post-vaccination samples, the presence of epitope spreading was well correlated with OS, whereas there were no significant correlations between epitope spreading to some particular antigens, such as HNRPL-501, SART2-93, MRP3-1293, and PSMA-624 (Table S2), and good clinical outcomes. Neither CTL nor IgG boosting was observed in the majority of sarcoma patients (>70%) or to the fact that only 20 patients were tested in this study.

In the present study, PPV has shown promising clinical benefits in refractory sarcoma patients with a MST of 9.6 months and a MPFST of 4 months. Previously, second-line palliative chemotherapy for advanced soft tissue sarcoma patients was reported to show a MST of 8 months and a 23% PFST at 6 months.\(^{(24)}\) In addition, best supportive care for elderly advanced soft tissue sarcoma patients was shown to reveal a MST of 5.3 months.\(^{(25)}\) Compared to these previous studies in patients with similar disease conditions, our results suggest that PPV could be an attractive therapeutic modality for refractory sarcoma patients because of the safety and potential survival benefits. Of note, combined treatments with chemotherapy or radiotherapy did not affect antigen-specific immune responses, but deteriorated PFST and OS in patients receiving PPV, indicating that combined treatments would not be beneficial, although the numbers of patients were too small to conclude in this study.

In conclusion, PPV could be feasible for the vast majority of refractory sarcoma patients because of the safety and higher rates of immunological responses regardless of the presence of different sarcoma subtypes and various HLA-types.

Acknowledgments

This study was supported in part by grants from the Regional Innovation Cluster Program, by the Project for Development of Innovative Research on Cancer Therapeutics (P-Direct) of the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by the Sendai Kousei Hospital.

Disclosure Statement

Kyogo Itoh is a Chief Scientific Advisor for the Green Peptide Company, Ltd. The other authors declare that they have no competing interests.

References

1. Maki RG. Soft tissue sarcoma as a model disease to examine cancer immunotherapy. Curr Opin Oncol 2001; 13: 270–4.
2. Maki RG. Future directions for immunotherapeutic intervention against sarcomas. Curr Opin Oncol 2006; 18: 363–8.
3. Chawla SP, Staddon AP, Baker LH et al. Phase II study of mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 2012; 30: 78–84.
4. Pappo AS, Patel SR, Crowley J et al. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J Clin Oncol 2011; 29: 4541–7.
5. Jungbluth AA, Antonescu CR, Busam KJ et al. Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or C7T. Int J Cancer 2001; 94: 252–6.
6. Skabitza KM, Pambuccian S, Manivel JC, Skabitza AP. Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med 2008; 6: 23.
7. Ayyoub M, Taub RN, Keohan ML et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4: 7.
8. Ayyoub M, Brehm M, Metzhe G et al. SX5 antigens as tumor vaccine targets. Cancer Immun 2003; 3: 13.
9. Jacobs JF, Brasseur F, Hulsbergen-van de Kaa CA et al. Cancer-germline gene expression in pediatric solid tumors using quantitative real-time PCR. Int J Cancer 2007; 120: 67–74.
10. Sasada T, Komatsu N, Suekane S, Yamada A, Noguchi M, Itoh K. Overcoming the hurdles of randomized clinical trials of therapeutic cancer vaccines. Eur J Cancer 2010; 46: 1514–9.
11. Terasaki M, Shibui S, Narita Y et al. Phase I trial of a personalized peptide vaccine combination with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep 2010; 24: 795–801.
Supporting Information

Additional Supporting Information may be found in the online version of this article:

**Fig. S1.** Survival curves for patients treated with personalized peptide vaccination (PPV) with or without combination therapies.

**Table S1.** Information of peptide candidates used for personalized peptide vaccination (PPV).

**Table S2.** Epitope spreading status in sarcoma patients after personalized peptide vaccination (PPV).